Terns Pharmaceuticals (TERN) News Today $3.10 -0.22 (-6.63%) Closing price 04:00 PM EasternExtended Trading$3.11 +0.01 (+0.32%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six brokerages that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued aMarch 25 at 4:24 AM | marketbeat.comOppenheimer Remains a Buy on Terns Pharmaceuticals (TERN)March 25 at 12:37 AM | markets.businessinsider.comTerns Pharmaceuticals' (TERN) Market Perform Rating Reiterated at William BlairMarch 24 at 1:35 AM | americanbankingnews.comWilliam Blair Reaffirms Market Perform Rating for Terns Pharmaceuticals (NASDAQ:TERN)William Blair reiterated a "market perform" rating on shares of Terns Pharmaceuticals in a report on Friday.March 22, 2025 | marketbeat.comWilliam Blair Reaffirms Their Hold Rating on Terns Pharmaceuticals (TERN)March 22, 2025 | markets.businessinsider.comTerns Pharmaceuticals Reports 2024 Progress and OutlookMarch 22, 2025 | tipranks.comTerns Pharmaceuticals (NASDAQ:TERN) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPSTerns Pharmaceuticals (NASDAQ:TERN - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.06.March 21, 2025 | marketbeat.comTerns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate UpdatesMarch 20, 2025 | globenewswire.comThis Weight Loss Stock Could Skyrocket by 462%, According to Wall StreetMarch 9, 2025 | fool.comCandriam S.C.A. Buys New Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)Candriam S.C.A. bought a new stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 2,153,969 shares of the company's stock, valued at approximately $11March 8, 2025 | marketbeat.comTerns Pharmaceuticals (TERN) Projected to Post Quarterly Earnings on ThursdayTerns Pharmaceuticals (NASDAQ:TERN) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports.March 6, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Rating of "Moderate Buy" by AnalystsTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six research firms that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. TheMarch 1, 2025 | marketbeat.comWilliam Blair Initiates Coverage on Terns Pharmaceuticals (NASDAQ:TERN)William Blair assumed coverage on shares of Terns Pharmaceuticals in a report on Friday. They set a "market perform" rating on the stock.March 1, 2025 | marketbeat.comTerns Pharmaceuticals initiated with a Market Perform at William BlairMarch 1, 2025 | markets.businessinsider.comWilliam Blair Initiates Coverage of Terns Pharmaceuticals (TERN) with Market Perform RecommendationMarch 1, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Vericel (VCEL) and Terns Pharmaceuticals (TERN)February 27, 2025 | markets.businessinsider.comIts CEO died. The company scrapped a promising program. Now, for their 2nd act.February 26, 2025 | finance.yahoo.comTerns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)February 26, 2025 | globenewswire.comTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial OfficerFebruary 25, 2025 | finanznachrichten.deTerns Pharmaceuticals sees cash runway into 2028February 25, 2025 | markets.businessinsider.comMizuho Securities Remains a Buy on Terns Pharmaceuticals (TERN)February 25, 2025 | markets.businessinsider.comTerns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare ConferenceFebruary 25, 2025 | globenewswire.comTerns Pharmaceuticals appoints Andrew Gengos as CFOFebruary 24, 2025 | markets.businessinsider.comTerns Pharmaceuticals Appoints Andrew Gengos as Chief Financial OfficerFebruary 24, 2025 | globenewswire.comTerns Pharmaceuticals Appoints Robert Azelby to Board of DirectorsFebruary 20, 2025 | globenewswire.comTerns Pharmaceuticals stock hits 52-week low at $4.16February 13, 2025 | msn.comTerns Pharmaceuticals announces CFO transition and consulting agreementFebruary 6, 2025 | msn.comTerns Pharmaceuticals CFO Resignation and Leadership TransitionFebruary 6, 2025 | tipranks.comTerns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 5, 2025 | globenewswire.comNovartis CEO discusses search for obesity deals with WSJFebruary 4, 2025 | markets.businessinsider.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Insider Melita Sun Jung Buys 2,250 SharesFebruary 4, 2025 | insidertrades.comMelita Sun Jung Acquires 2,250 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) StockTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) insider Melita Sun Jung purchased 2,250 shares of the stock in a transaction that occurred on Saturday, November 30th. The stock was bought at an average cost of $5.11 per share, for a total transaction of $11,497.50. Following the acquisition, the insider now directly owns 2,250 shares in the company, valued at $11,497.50. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.February 3, 2025 | marketbeat.comTerns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)February 3, 2025 | globenewswire.comTerns Pharmaceuticals stock hits 52-week low at $4.32January 29, 2025 | msn.comNovo Nordisk's Ozempic gets FDA approval for kidney diseaseJanuary 28, 2025 | msn.comTerns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | globenewswire.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Insider Sells $25,586.51 in StockJanuary 7, 2025 | insidertrades.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Insider Emil Kuriakose Sells 4,481 SharesTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) insider Emil Kuriakose sold 4,481 shares of the company's stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $5.71, for a total value of $25,586.51. Following the sale, the insider now owns 54,269 shares in the company, valued at approximately $309,875.99. This trade represents a 7.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.January 6, 2025 | marketbeat.comJill M. Quigley Sells 6,240 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) StockTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) Director Jill M. Quigley sold 6,240 shares of the business's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $5.72, for a total value of $35,692.80. Following the sale, the director now directly owns 8,760 shares of the company's stock, valued at approximately $50,107.20. This trade represents a 41.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.January 6, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) CFO Mark J. Vignola Sells 8,129 SharesTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CFO Mark J. Vignola sold 8,129 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $5.72, for a total transaction of $46,497.88. Following the sale, the chief financial officer now directly owns 83,811 shares of the company's stock, valued at approximately $479,398.92. This trade represents a 8.84 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.January 6, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Director Jill M. Quigley Sells 8,760 SharesTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) Director Jill M. Quigley sold 8,760 shares of the firm's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $5.79, for a total transaction of $50,720.40. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.January 6, 2025 | marketbeat.comMark J. Vignola Sells 9,059 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) StockTerns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) CFO Mark J. Vignola sold 9,059 shares of the company's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $5.80, for a total value of $52,542.20. Following the transaction, the chief financial officer now directly owns 74,752 shares in the company, valued at $433,561.60. This represents a 10.81 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.January 6, 2025 | marketbeat.comTerns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)January 2, 2025 | globenewswire.comTerns Pharmaceuticals Positioned for Success with Promising Oral Therapy TERN-601 Amid Novo Nordisk’s SetbackDecember 20, 2024 | markets.businessinsider.comTerns Pharmaceuticals (NASDAQ:TERN) Shares Down 4.7% - Time to Sell?Terns Pharmaceuticals (NASDAQ:TERN) Shares Down 4.7% - Here's What HappenedDecember 18, 2024 | marketbeat.comIs Terns Pharmaceuticals, Inc. (TERN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?December 16, 2024 | insidermonkey.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Stake Reduced by Fmr LLCFmr LLC decreased its position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Free Report) by 57.6% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,172,524 shares of the company's stock after selling 1,594,572 shares duringDecember 12, 2024 | marketbeat.comTerns Pharmaceuticals CEO & Director Acquires 423% More StockDecember 11, 2024 | uk.finance.yahoo.comAmy L. Burroughs Purchases 15,450 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) StockDecember 10, 2024 | insidertrades.comAnalysts Offer Insights on Healthcare Companies: Haemonetics (HAE) and Terns Pharmaceuticals (TERN)December 6, 2024 | markets.businessinsider.com Remove Ads Get Terns Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter. Email Address TERN Media Mentions By Week TERN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TERN News Sentiment▼0.730.89▲Average Medical News Sentiment TERN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TERN Articles This Week▼113▲TERN Articles Average Week Remove Ads Get Terns Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Calliditas Therapeutics AB (publ) News Today Iovance Biotherapeutics News Today Syndax Pharmaceuticals News Today Aurinia Pharmaceuticals News Today Spyre Therapeutics News Today Enliven Therapeutics News Today Mineralys Therapeutics News Today Nurix Therapeutics News Today Vir Biotechnology News Today Intellia Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TERN) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Terns Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Terns Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TERN Stock Free TERN Stock Alerts